Published in Research

BioTissue unveils breakthrough in dry eye treatment at Academy 2023

Findings of a new multi-center, retrospective study conducted on patients with moderate to severe dry eye disease (DED) treated with BioTissue’s self-retained Prokeraâ Slim Amniotic Membrane corneal bandage show significantly improved patient outcomes in less time.

The research will be presented in a poster at the American Academy of Optometry 2023 meeting this week in New Orleans.

“The findings presented highlight the progress we’ve made in enhancing treatment options for individuals affected by DED, further emphasizing our focus on empowering healthcare professionals to elevate the standards of care and make a positive difference in the lives of their patients,” said BioTissue CEO Ted Davis.

The poster, Sutureless Cryopreserved Amniotic Membrane for Moderate to Severe Dry Eye with Short Treatment Duration by Damon Dierker, OD, FAAO, et al., reexamines the traditional five-to-seven-day treatment duration for sutureless Cryopreserved Amniotic Membrane in addressing DED.

In the study, nine patients were treated with Prokera Slim for just two days and were observed at one-week, one-month, and three-month time intervals.

The main result of the study revealed a significant improvement in Dry Eye Workshop (DEWS) scores one-week, one-month, and three-months post-treatment.

Baseline scores improved from 3.1 +/- 0.6 at baseline to 1.50 +/- 0.5 at one-week (p=0.006) and 1.2 +/- 0.4 at both one- and three-months (p=0.004) with no reported complications or adverse effects throughout the study.

This underscores the significant relief provided by Prokera Slim and the enhancement of clinical signs in DED for a duration of up to three-months.

“This study has allowed us the opportunity to reexamine the conventional approach to treating moderate to severe DED by significantly decreasing the required treatment duration for patients,” said Dr. Dierker. “Administering Prokera Slim for just two days and seeing substantial improvements over a three-month period emphasizes the potential for shorter, more efficient treatments in the future.”

The poster (#59) was presented on Thursday, October 12, in Exhibit Hall D from 4:30 p.m. to 6:30 p.m.